All In MedTech

Device Trial Radar · NCT05947708

The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

A Post-Market, Single Blind, Randomized Clinical Prospective Study on Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

Last checked: Nov 20, 2026Latest source record: Jul 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Sep 15, 2019

Primary completion

Oct 15, 2019

Study completion Jan 15, 2020

Sponsor

Lead sponsor
Outset MedicalNot on our public-company list
Sponsor type
Industry
Collaborators
White Plains Hospital
First posted
Jul 17, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study Goal is to determine the impact of dialysate flow rate (Qd) on Subject reported dialysis related symptoms and on time to recovery post dialysis.

Conditions

  • End Stage Renal Disease on Dialysis

Interventions

  • Dialysate Flow RateDevice

    Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adequacy of Chronic DialysisTime frame: 4 weeks

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Outset Medical

    San Jose, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.